EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells

Chen,Peijie; Huang,Yan; Zhang,Bo; Wang,Qiuquan; Bai,Peiming

doi:10.3892/ol.2014.2093

EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells

Authors:
- Peijie Chen
- Yan Huang
- Bo Zhang
- Qiuquan Wang
- Peiming Bai
View Affiliations

Affiliations: Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2093
Pages: 41-46

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

EphA2 is persistently overexpressed and functionally changed in numerous human cancers. However, to the best of our knowledge, the role that EphA2 plays in prostate cancer is not entirely clear. To investigate the roles of EphA2 in the development and progression of prostate cancer, the present study initially evaluated the roles of the EphA2 protein in LNCaP prostate cancer cells using recombinant plasmid, western blot analysis, flow cytometry, Matrigel invasion chamber and the cell counting kit‑8 assay. An immunohistochemistry assay was also conducted to observe the effects of EphA2 in prostate cancer tissues. The results demonstrated that the LNCaP human prostate cancer cells that were transfected with pcDNA3.1(+) plasmid‑mediated pcDNA3.1(+)‑EphA2, markedly enhanced the cell growth and invasion in vitro. Additionally, EphA2 was overexpressed in prostate cancer specimens and the expression of EphA2 was significantly associated with Gleason grade, total prostate‑specific antigen, advanced clinical stage and lymph node metastasis. Collectively, these results demonstrate that EphA2 is involved in malignant cell behavior and is a potential therapeutic target in human prostate cancer.

View Figures

View References

1	Lindberg RA and Hunter T: cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol. 10:6316–6324. 1990.
2	Sulman EP, Tang XX, Allen C, et al: ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics. 40:371–374. 1997.
3	Cheng N, Brantley DM and Chen J: The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 13:75–85. 2002.
4	Kamat AA, Coffey D, Merritt WM, et al: EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 115:2684–2692. 2009.
5	Liu F, Park PJ, Lai W, et al: A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 66:10815–10823. 2006.
6	Lu M, Miller KD, Gokmen-Polar Y, et al: EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 63:3425–3429. 2003.
7	Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosinase kinase in prostate cancer. Prostate. 41:275–280. 1999.
8	Landen CN Jr, Chavez-Reyes A, Bucana C, et al: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910–6918. 2005.
9	Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res. 12:353–360. 2006.
10	Herrem CJ, Tatsumi T, Olson KS, et al: Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res. 11:226–231. 2005.
11	Lin YG, Han LY, Kamat AA, et al: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 109:332–340. 2007.
12	Brantley-Sieders DM, Zhuang G, Hicks D, et al: The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 118:64–78. 2008.
13	Taddei ML, Parri M, Angelucci A, et al: EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res. 9:149–160. 2011.
14	Kinch MS, Clark GJ, Der CJ and Burridge K: Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol. 130:461–471. 1995.
15	Prout GR Jr: Proceedings: Diagnosis and staging of prostatic carcinoma. Cancer. 32:1096–1103. 1973.
16	Zeng G, Hu Z, Kinch MS, et al: High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol. 163:2271–2276. 2003.
17	Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2:1707–1714. 2006.
18	Margaryan NV, Strizzi L, Abbott DE, et al: EphA2 as a promoter of melanoma tumorigenity. Cancer Biol Ther. 8:279–288. 2009.
19	Parri M, Taddei ML, Bianchini F, et al: EphA2 reexpression prompts invasion of melanoma cells shifting from mesenehymal to amoeboid-like motility style. Cancer Res. 69:2072–2081. 2009.
20	Lu C, Shahzad MM, Wang H, et al: EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 7:1098–2103. 2008.
21	Taddei ML, Parri M, Angelucci A, et al: Kinase-dependent and-independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol. 174:1492–1503. 2009.
22	Petty A, Myshkin E, Qin H, et al: A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 7:e421202012.
23	Van den Broeck A, Vankelecom H, Van Eijsden R, et al: Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res. 31:682012.
24	Coffman KT, Hu M, Carles-Kinch K, et al: Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 63:7907–7912. 2003.
25	Liu DP, Wang Y, Koeffler HP and Xie D: Ephrin-A1 is a negative regulator in glioma through downregulation of EphA2 and FAK. Int J Oncol. 30:865–871. 2007.
26	Mohammed KA, Wang X, Goldberg EP, et al: Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. Am J Cancer Res. 1:419–431. 2011.